Effect of ethanolic extract of Zingiber officinale on dyslipidaemia in diabetic rats

被引:140
作者
Bhandari, U [1 ]
Kanojia, R [1 ]
Pillai, KK [1 ]
机构
[1] Hamdard Univ, Fac Pharm, Dept Pharmacol, New Delhi 110062, India
关键词
Zingiber officinale; lipid peroxidation; dyslipidaemia; streptozotocin;
D O I
10.1016/j.jep.2004.11.011
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
The lipid lowering and antioxidant potential of ethanolic extract of Zingiber officinale Roscoe (family, Zingiberaceae) was evaluated in streptozotocin (STZ)-induced diabetes in rats. Ethanolic extract of Zingiber officinale (200 mg/kg) fed orally for 20 days produced, significant antihyperglycaemic effect (P<0.01) in diabetic rats. Further, the extract treatment also lowered serum total cholesterol, triglycerides and increased the HDL-cholesterol levels when compared with pathogenic diabetic rats (P<0.01). STZ-treatment also induced a statistically significant increase in liver and pancreas lipid peroxide levels (P<0.01) as compared to normal healthycontrol rats. Zingiber officinale extract treatment lowered the liver and pancreas thiobarbituric acid reactive substance., (TBARS) values (P<0.01) as compared to pathogenic diabetic rats. The results of test drug were comparable to gliclazide (25 mg/kg, orally), a standard antihyperglycaemic agent. The results indicate that ethanolic extract of Zingiber officinale Roscoe can protect the tissues from lipid peroxidation. The extract also exhibit significant lipid lowering activity in diabetic rats. The present study is the first pilot study to assess the potential of Zingiber officinale in diabetic dyslipidaemia. (C) 2004 Published by Elsevier Ireland Ltd.
引用
收藏
页码:227 / 230
页数:4
相关论文
共 27 条
[1]  
Afzal M, 2001, Drug Metabol Drug Interact, V18, P159
[2]  
Ahmed R. S., 1997, Indian Journal of Experimental Biology, V35, P841
[3]  
Ahmed Rafat S., 2000, Indian Journal of Experimental Biology, V38, P604
[4]  
Akhtar F.M., 1980, J PAK MED ASSOC, V34, P239
[5]  
[Anonymous], INT J DIABETES MELLI
[6]   Current, new and future treatments in dyslipidaemia and atherosclerosis [J].
Chong, PH ;
Bachenheimer, BS .
DRUGS, 2000, 60 (01) :55-93
[7]  
DEMACKER PNM, 1980, CLIN CHEM, V26, P1775
[8]  
FOSSATI P, 1982, CLIN CHEM, V28, P2077
[9]  
Fuhrman B, 2000, J NUTR, V130, P1124
[10]  
GINGLIANO D, 1996, DIABETES CARE, V19, P257